BRPI0818726A2 - Compostos de 1,2,4-triazin-3,5-diona para tratar desordens que respondem à modulação do receptor d3 de dopamina. - Google Patents

Compostos de 1,2,4-triazin-3,5-diona para tratar desordens que respondem à modulação do receptor d3 de dopamina.

Info

Publication number: BRPI0818726A2
Authority: BR; Brazil
Prior art keywords: triazin; dopamine; treat disorders; receptor modulation; disorders responsive
Prior art date: 2007-11-02

Application number

Other languages

English (en)

Inventor

Wilfried Braje

Sean Colm Turner

Andreas Haupt

Udo Lange

Hervé Geneste

Karla Drescher

Liliane Unger

Ana Lucia Jongen-Relo

Anton Bespalov

Original Assignee

Abbott Gmbh & Co Kg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-11-02

Filing date

2008-10-31

Publication date

2015-04-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40210491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0818726(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-10-31 Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg

2015-04-22 Publication of BRPI0818726A2 publication Critical patent/BRPI0818726A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Addiction (AREA)
Psychiatry (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Obesity (AREA)
Anesthesiology (AREA)
Gynecology & Obstetrics (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Nutrition Science (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

BRPI0818726 2007-11-02 2008-10-31 Compostos de 1,2,4-triazin-3,5-diona para tratar desordens que respondem à modulação do receptor d3 de dopamina. BRPI0818726A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP07119927		2007-11-02
PCT/EP2008/064795 WO2009056625A1 (en)	2007-11-02	2008-10-31	1,2,4,-triazin-3,5-dione compounds for treating disorders that respond to modulation of the dopamine d3 receptor

Publications (1)

Publication Number	Publication Date
BRPI0818726A2 true BRPI0818726A2 (pt)	2015-04-22

Family

ID=40210491

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0818726 BRPI0818726A2 (pt)	2007-11-02	2008-10-31	Compostos de 1,2,4-triazin-3,5-diona para tratar desordens que respondem à modulação do receptor d3 de dopamina.

Country Status (28)

Country	Link
US (1)	US8492540B2 (pt)
EP (1)	EP2217593B1 (pt)
JP (1)	JP5559694B2 (pt)
KR (1)	KR20100094491A (pt)
CN (1)	CN101932574B (pt)
AR (1)	AR069150A1 (pt)
AT (1)	ATE556069T1 (pt)
AU (1)	AU2008320814B2 (pt)
BR (1)	BRPI0818726A2 (pt)
CA (1)	CA2704533C (pt)
CL (1)	CL2008003253A1 (pt)
CO (1)	CO6280473A2 (pt)
CR (1)	CR11410A (pt)
DO (1)	DOP2010000126A (pt)
EC (1)	ECSP10010227A (pt)
ES (1)	ES2386691T3 (pt)
IL (1)	IL205468A0 (pt)
MX (1)	MX2010004830A (pt)
MY (1)	MY154066A (pt)
NZ (1)	NZ585051A (pt)
PA (1)	PA8802101A1 (pt)
PE (1)	PE20090950A1 (pt)
RU (1)	RU2478633C2 (pt)
TW (1)	TWI463984B (pt)
UA (1)	UA99634C2 (pt)
UY (1)	UY31448A1 (pt)
WO (1)	WO2009056625A1 (pt)
ZA (1)	ZA201003593B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9505753B2 (en)	2012-08-08	2016-11-29	The Johns Hopkins University	Inhibitors of D-amino acid oxidase
US9376396B2 (en)	2012-10-22	2016-06-28	AbbVie Deutschland GmbH & Co. KG	Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor
AR095264A1 (es)	2013-03-15	2015-09-30	Abbvie Deutschland	Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3
UY35420A (es)	2013-03-15	2014-10-31	Abbvie Inc	Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3
KR102643833B1 (ko)	2022-06-30	2024-03-06	현대제철 주식회사	이강종 연연주시 강종 예측 정합성 증대 방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4425143A1 (de)	1994-07-15	1996-01-18	Basf Ag	Substituierte Pyrimidinverbindungen und deren Verwendung
DE4425144A1 (de)	1994-07-15	1996-01-18	Basf Ag	Triazolverbindungen und deren Verwendung
DE4425146A1 (de)	1994-07-15	1996-01-18	Basf Ag	Verwendung heterocyclischer Verbindungen
FR2727682A1 (fr) *	1994-12-02	1996-06-07	Pf Medicament	Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament
DE19728996A1 (de)	1997-07-07	1999-01-14	Basf Ag	Triazolverbindungen und deren Verwendung
FR2769913B1 (fr) *	1997-10-16	2000-03-10	Pf Medicament	Nouveaux derives cyclohexaniques difonctionnalises en 1, 4, leur preparation et leur application therapeutique humaine
DE10311065A1 (de)	2003-03-13	2004-09-23	Abbott Gmbh & Co. Kg	Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung
JP2004359689A (ja) *	2003-06-05	2004-12-24	Abbott Gmbh & Co Kg	ドーパミンｄ３受容体のモジュレーションに反応する障害の治療に適するトリアゾール化合物
DE102004027359A1 (de)	2004-06-04	2005-12-29	Abbott Gmbh & Co. Kg	Pyridin-2-onverbindungen und deren Verwendung
DE102004027358A1 (de)	2004-06-04	2005-12-29	Abbott Gmbh & Co. Kg	Pyrimidinverbindungen und ihre Verwendung
ATE452134T1 (de) *	2004-08-09	2010-01-15	Abbott Gmbh & Co Kg	Zur behandlung von auf eine modulation des dopamin-d3-rezeptors ansprechende erkrankungen geeignete 4-piperazinylpyrimidinverbindungen
WO2006058753A1 (en) *	2004-12-02	2006-06-08	Abbott Gmbh & Co. Kg	Triazole compounds suitable for treating disorders that respond to modulaiont of the dopamine d3 receptor
DE102004061593A1 (de)	2004-12-21	2006-06-22	Abbott Gmbh & Co. Kg	Substituierte N-heterocyclische Verbindungen und ihre therapeutische Verwendung
CN101796033A (zh) *	2007-06-28	2010-08-04	英特维特国际股份有限公司	作为cb1拮抗剂的取代的哌嗪

2008
- 2008-10-29 PA PA20088802101A patent/PA8802101A1/es unknown
- 2008-10-30 CL CL2008003253A patent/CL2008003253A1/es unknown
- 2008-10-30 TW TW097141858A patent/TWI463984B/zh not_active IP Right Cessation
- 2008-10-31 JP JP2010531532A patent/JP5559694B2/ja not_active Expired - Fee Related
- 2008-10-31 CA CA2704533A patent/CA2704533C/en not_active Expired - Fee Related
- 2008-10-31 KR KR1020107011975A patent/KR20100094491A/ko not_active Ceased
- 2008-10-31 AU AU2008320814A patent/AU2008320814B2/en not_active Ceased
- 2008-10-31 EP EP08844723A patent/EP2217593B1/en active Active
- 2008-10-31 AT AT08844723T patent/ATE556069T1/de active
- 2008-10-31 CN CN200880124247.7A patent/CN101932574B/zh not_active Expired - Fee Related
- 2008-10-31 WO PCT/EP2008/064795 patent/WO2009056625A1/en not_active Ceased
- 2008-10-31 ES ES08844723T patent/ES2386691T3/es active Active
- 2008-10-31 NZ NZ585051A patent/NZ585051A/en not_active IP Right Cessation
- 2008-10-31 UA UAA201006793A patent/UA99634C2/ru unknown
- 2008-10-31 US US12/740,714 patent/US8492540B2/en not_active Expired - Fee Related
- 2008-10-31 RU RU2010122337/04A patent/RU2478633C2/ru not_active IP Right Cessation
- 2008-10-31 BR BRPI0818726 patent/BRPI0818726A2/pt not_active IP Right Cessation
- 2008-10-31 MY MYPI2010001969A patent/MY154066A/en unknown
- 2008-10-31 AR ARP080104789A patent/AR069150A1/es unknown
- 2008-10-31 MX MX2010004830A patent/MX2010004830A/es active IP Right Grant
- 2008-10-31 PE PE2008001865A patent/PE20090950A1/es not_active Application Discontinuation
- 2008-10-31 UY UY31448A patent/UY31448A1/es not_active Application Discontinuation
2010
- 2010-04-29 IL IL205468A patent/IL205468A0/en unknown
- 2010-04-29 DO DO2010000126A patent/DOP2010000126A/es unknown
- 2010-05-03 CR CR11410A patent/CR11410A/es unknown
- 2010-05-20 ZA ZA2010/03593A patent/ZA201003593B/en unknown
- 2010-06-01 CO CO10065792A patent/CO6280473A2/es active IP Right Grant
- 2010-06-01 EC EC2010010227A patent/ECSP10010227A/es unknown

Also Published As

Publication number	Publication date
CA2704533C (en)	2016-09-06
RU2478633C2 (ru)	2013-04-10
ES2386691T3 (es)	2012-08-27
UY31448A1 (es)	2009-05-29
CN101932574A (zh)	2010-12-29
ATE556069T1 (de)	2012-05-15
US20100311755A1 (en)	2010-12-09
AU2008320814A1 (en)	2009-05-07
CA2704533A1 (en)	2009-05-07
PE20090950A1 (es)	2009-08-08
DOP2010000126A (es)	2010-06-15
IL205468A0 (en)	2010-12-30
TWI463984B (zh)	2014-12-11
JP2011502971A (ja)	2011-01-27
ECSP10010227A (es)	2010-08-31
CO6280473A2 (es)	2011-05-20
NZ585051A (en)	2012-03-30
UA99634C2 (ru)	2012-09-10
CR11410A (es)	2010-09-13
KR20100094491A (ko)	2010-08-26
CL2008003253A1 (es)	2009-11-13
AU2008320814B2 (en)	2013-07-11
MY154066A (en)	2015-04-30
US8492540B2 (en)	2013-07-23
JP5559694B2 (ja)	2014-07-23
TW200927132A (en)	2009-07-01
EP2217593A1 (en)	2010-08-18
ZA201003593B (en)	2011-02-23
WO2009056625A1 (en)	2009-05-07
MX2010004830A (es)	2010-10-20
HK1146628A1 (en)	2011-06-24
CN101932574B (zh)	2014-07-23
EP2217593B1 (en)	2012-05-02
PA8802101A1 (es)	2009-08-26
RU2010122337A (ru)	2011-12-10
AR069150A1 (es)	2009-12-30

Publication	Publication Date	Title
BRPI0923786A2 (pt)	2016-07-26	compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos
BRPI0919024A2 (pt)	2019-09-24	compostos que seletivamente modulam o receptor cb2
EP2129224A4 (en)	2011-01-05	5,6-dihydro-1H-pyridin-2-one compounds
EP2157859A4 (en)	2011-01-12	INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE
BRPI0814958A2 (pt)	2015-02-03	Compostos de indazol ou indol, composição, e, método para preparar uma composição.
CL2007003049A1 (es)	2008-05-16	Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos.
EP2214646A4 (en)	2014-08-27	DENDRIMER TO DELAY RELIEF OF LINKS
BRPI0815717A2 (pt)	2015-02-10	Compostos de imidazopirazina.
ATE540040T1 (de)	2012-01-15	Dioxabicycloä3.2.1üoctan-2,3,4-triolderivate
PT2430921T (pt)	2017-09-15	Fungicidas de benzeno substituído
EP2240490A4 (en)	2011-06-15	ORGANIC CONNECTIONS
BRPI0813449A2 (pt)	2014-12-23	Formas de dosagem sólida ou semissólida de liberação modificada.
BRPI0922384A2 (pt)	2016-01-26	"manipulador de suprimento para equipamento".
CL2007002424A1 (es)	2008-02-08	Compuestos derivados de isoxazolidina; composicion farmaceutica que comprende a dicho compuesto, util para el tratamiento de trastornos asociados con hiperproliferacion como cancer.
BRPI0906607A2 (pt)	2015-07-14	Agentes de coalescência eficazes.
DK2205562T3 (da)	2011-06-14	1,1,1-trifluor-2-hydroxy-3-phenylpropanderivater
EP2013196A4 (en)	2010-10-27	DISUBSTITUTED ANILINE COMPOUNDS
FI20075517L (fi)	2009-01-06	Kenkäpuristinhihna
BRPI0917815A2 (pt)	2015-08-18	Combinação herbicida que contém difluormetano sulfonilanilidas substituídas por dimetoxitriazilina
EP2120578A4 (en)	2013-01-30	KINASE INHIBITORS COMPOUNDS
BRPI0815059A2 (pt)	2015-02-10	Derivado de 1,3-di-hidroisoindol
BRPI0916363A2 (pt)	2018-05-29	derivados de 4,5-di-hidro-oxazol-2-ila
CL2008000430A1 (es)	2008-08-18	Compuestos derivados de heterociclos condensados sustituidos; composicion farmaceutica que comprende a dichos compuestos, utiles para el tratamiento de una o mas condiciones asociadas con receptores adrenergicos a2c, tales como congestion asociada a
EP2117306A4 (en)	2010-02-10	NEUROGENIC COMPOUNDS
BRPI0818726A2 (pt)	2015-04-22	Compostos de 1,2,4-triazin-3,5-diona para tratar desordens que respondem à modulação do receptor d3 de dopamina.

Legal Events

Date	Code	Title	Description
2016-09-20	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 8A ANUIDADE.
2017-01-17	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.